ClinicalTrials.gg
CompletedNCT03745651Updated Sep 28, 2023Results posted

TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

A Phase 3 interventional study of Ruxolitinib cream and Vehicle cream in Atopic Dermatitis, sponsored by Incyte Corporation. Completed at 66 sites in 7 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
618
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing ruxolitinib in Dermatitis, Atopic — 2 open to participants now, 3 under way, 1 of them phase 3. ruxolitinib · Dermatitis, Atopic.

Enrollment
2nd of 15
618 · median 77
Started
2018
with 1 other
Phase 3
6 of 15
none open now
Registered
3rd of 15
by date
Lead sponsor
13 of 15
Incyte Corporation

Among the 15 studies testing ruxolitinib in Dermatitis, Atopic, this one is the 2nd largest by enrollment, is one of 2 that started in 2018, is one of 6 in phase 3, and was the 3rd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 15 studies testing ruxolitinib in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing ruxolitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy of ruxolitinib cream in adolescents and adults with atopic dermatitis (AD).

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • Atopic dermatitis
  • pruritus
  • eczema
  • topical therapy
  • JAK inhibitor
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adolescents aged ≥ 12 to 17 years, inclusive, and men and women aged ≥ 18 years.
  • Participants diagnosed with atopic dermatitis (AD) as defined by the Hanifin and Rajka criteria.
  • AD duration of at least 2 years.
  • Participants with an Investigator's Global Assessment (IGA) score of 2 to 3 at Screening and Baseline (VC Period) and 0 to 4 at Week 8 (LTS Period).
  • Participants with percentage body surface area (%BSA) (excluding scalp) of AD involvement of 3% to 20% at Screening and Baseline (VC Period) and 0% to 20% at Week 8 (LTS Period).
  • Participants who agree to discontinue all agents used to treat AD from Screening through the final follow-up visit.
  • Participants who have at least 1 "target lesion" that measures approximately 10 cm\^2 or more at Screening and Baseline. Lesion must be representative of the participant's disease state and not be located on the hands, feet, or genitalia.
  • Willingness to avoid pregnancy or fathering of children.

Exclusion criteria

Exclusion Criteria:

  • Unstable course of AD (spontaneously improving or rapidly deteriorating) as determined by the investigator in the 4 weeks prior to Baseline.
  • Concurrent conditions and history of other diseases:

    • .
    • Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before Baseline.
    • Active acute bacterial, fungal, or viral skin infection within 1 week before Baseline.
    • Any other concomitant skin disorder, pigmentation, or extensive scarring that, in the opinion of the investigator, may interfere with the evaluation of AD lesions or compromise participant safety.
    • Presence of AD lesions only on the hands or feet without prior history of involvement of other classical areas of involvement such as the face or the folds.
    • Other types of eczema.
  • Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
  • Use of any of the following treatments within the indicated before Baseline:

    • 5 half-lives or 12 weeks, whichever is longer - biologic agents (e.g. dupilumab).
    • 4 weeks - systemic or adrenocorticotropic hormone analogs, cyclosporin, methotrexate, azathioprine, or other systemic immunosuppressive or immunomodulating agents (e.g. mycophenolate or tacrolimus).
    • 2 weeks - immunizations and sedating antihistamines, unless on long-term stable regimen (nonsedating antihistamines are permitted).
    • 1 week - use of other topical treatments for AD (other than bland emollients). Diluted sodium hypochlorite "bleach" baths are allowed as long as they do not exceed 2 baths per week and their frequency remains the same throughout the study.
  • Participants who have previously received Janus kinase (JAK) inhibitors, systemic or topical.
  • Ultraviolet (UV) light therapy or prolonged exposure to natural or artificial sources of UV radiation within 2 weeks prior to Baseline and/or intention to have such exposure during the study, which is thought by the investigator to potentially impact the participant's AD.
  • Positive serology test results at screening for (HIV) antibody.
  • Liver function tests: (AST) or alanine aminotransferase (ALT) ≥ 2 × (ULN); alkaline phosphatase and/or > 1.5 × ULN (isolated bilirubin > 1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin \< 35%).
  • Pregnant or lactating participants, or those considering pregnancy.
  • History of alcoholism or drug addiction within 1 year before screening or current alcohol or drug use that, in the opinion of the investigator, will interfere with the participant's ability to comply with the administration schedule and study assessments.
  • Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before Baseline with another medication or current enrollment in another investigational drug protocol.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
618 participants (actual)

Study arms

  • Placebo comparator
    Vehicle Control (VC) Period: Vehicle Cream BID

    Participants received ruxolitinib matching vehicle cream, applied topically to the affected areas as a thin film twice daily (BID) 8 hours apart from Day 1 up to Week 8. Participants applied cream BID to areas identified at Baseline even if the areas improved.

    Drug: Vehicle cream

  • Experimental
    VC Period: Ruxolitinib 0.75% Cream BID

    Participants received ruxolitinib 0.75% cream, applied topically to the affected areas as a thin film BID 8 hours apart from Day 1 up to Week 8. Participants applied cream BID to areas identified at Baseline even if the areas improved.

    Drug: Ruxolitinib cream

  • Experimental
    VC Period: Ruxolitinib 1.5% Cream BID

    Participants received ruxolitinib 1.5% cream, applied topically to the affected areas as a thin film BID 8 hours apart from Day 1 up to Week 8. Participants applied cream BID to areas identified at Baseline even if the areas improved.

    Drug: Ruxolitinib cream

  • Experimental
    Long-Term Safety (LTS) Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID

    Participants who applied vehicle cream during the VC Period were randomized at Week 8 to apply ruxolitinib 0.75% cream, topically to the affected areas as a thin film BID as needed from Week 8 up to Week 52. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.

    Drug: Ruxolitinib cream

  • Experimental
    LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID

    Participants who applied vehicle cream during the VC Period were randomized at Week 8 to apply ruxolitinib 1.5% cream, topically to the affected areas as a thin film BID as needed from Week 8 up to Week 52. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.

    Drug: Ruxolitinib cream

  • Experimental
    LTS Period: Ruxolitinib 0.75% Cream BID

    Participants who applied ruxolitinib 0.75% cream during the VC Period, continued applying ruxolitinib 0.75% cream, topically to the affected areas as a thin film BID as needed from Week 8 up to Week 52. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.

    Drug: Ruxolitinib cream

  • Experimental
    LTS Period: Ruxolitinib 1.5% Cream BID

    Participants who applied ruxolitinib 1.5% cream during the VC Period, continued applying ruxolitinib 1.5% cream, topically to the affected areas as a thin film BID as needed from Week 8 up to Week 52. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.

    Drug: Ruxolitinib cream

Interventions

  • Ruxolitinib 0.75% or 1.5% cream.

    Also known as: INCB018424 phosphate cream

  • DrugVehicle cream

    Ruxolitinib matching vehicle cream.

06

What researchers measure

Primary outcomes

  1. VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8

    The IGA is an overall eczema severity rating on a 5-point scale ranging from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting. The IGA-TS is defined as an IGA score of 0 (clear skin) or 1 (almost clear skin) with ≥ 2 grade improvement from Baseline.

    Time frame: Baseline to Week 8

Secondary outcomes

  1. VC Period: Percentage of Participants Who Achieved Eczema Area and Severity Index 75 (EASI75) at Week 8

    EASI scoring system examines 4 areas of the body (head/neck, trunk, upper limbs, and lower limbs) and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe). Half scores are allowed between severities 1, 2 and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 and the severity strata are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI75 responder was defined as a participant achieving 75% or greater improvement from Baseline in EASI score.

    Time frame: Baseline to Week 8

  2. VC Period: Percentage of Participants With a ≥ 4-Point Improvement in Itch Numerical Rating Scale (NRS) Score From Baseline to Week 8

    The Itch NRS is a daily participant-reported measure (24-hour recall), of the worst level of itch intensity using a diary. Participants are asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours.

    Time frame: Baseline to Week 8

  3. VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form - Sleep Disturbance (8b - 24-Hour Recall) Score at Week 8

    The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance.

    Time frame: Baseline to Week 8

  4. VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep-Related Impairment (8a - 24-Hour Recall) Score at Week 8

    The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment. Each item asks the participant to rate the severity of the participant's sleep impairment.

    Time frame: Baseline to Week 8

  5. VC Period: Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) and Treatment-Emergent Serious Adverse Event (SAE)

    An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or an important medical event may be considered serious when, based on appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above. A TEAE or treatment emergent SAE is any AE or SAE either reported for first time or worsening of a pre-existing event after first dose of study drug.

    Time frame: From date of randomization up to Week 8

  6. LTS Period: Percentage of Participants With at Least One TEAE and Treatment Emergent SAE

    An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or an important medical event may be considered serious when, based on appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above. A TEAE or treatment emergent SAE is any AE or SAE either reported for first time or worsening of a pre-existing event after first dose of study drug.

    Time frame: From first dose date in LTS Period (Week 8) until last follow-up visit (up to 52 weeks)

  7. VC Period: Percentage of Participants Who Achieved an IGA-TS at Weeks 2 and 4

    The IGA is an overall eczema severity rating on a 5-point scale ranging from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting. The IGA-TS is defined as an IGA score of 0 (clear skin) or 1 (almost clear skin) with ≥ 2 grade improvement from Baseline.

    Time frame: Baseline to Weeks 2 and 4

  8. VC Period: Percentage of Participants Achieving an IGA of 0 or 1

    The IGA is an overall eczema severity rating on a 5-point scale ranging from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting.

    Time frame: Weeks 2, 4 and 8

  9. LTS Period: Percentage of Participants Achieving an IGA of 0 or 1

    The IGA is an overall eczema severity rating on a 5-point scale ranging from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting.

    Time frame: Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  10. VC Period: Percentage of Participants With a ≥ 4-Point Improvement in Itch NRS Score From Baseline to Weeks 2 and 4

    The Itch NRS is a daily participant-reported measure (24-hour recall), of the worst level of itch intensity using a diary. Participants are asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours.

    Time frame: Baseline to Weeks 2 and 4

  11. VC Period: Percentage of Participants Who Achieved EASI50

    EASI scoring system examines 4 areas of the body (head/neck, trunk, upper limbs, and lower limbs) and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe). Half scores are allowed between severities 1, 2 and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 and the severity strata are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI50 responder was defined as a participant achieving 50% or greater improvement from Baseline in EASI score.

    Time frame: Baseline to Weeks 2, 4 and 8

  12. VC Period: Percentage of Participants Who Achieved EASI75 at Weeks 2 and 4

    EASI scoring system examines 4 areas of the body (head/neck, trunk, upper limbs, and lower limbs) and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe). Half scores are allowed between severities 1, 2 and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 and the severity strata are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI75 responder was defined as a participant achieving 75% or greater improvement from Baseline in EASI score.

    Time frame: Baseline to Weeks 2 and 4

  13. VC Period: Percentage of Participants Who Achieved EASI90

    EASI scoring system examines 4 areas of the body (head/neck, trunk, upper limbs, and lower limbs) and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe). Half scores are allowed between severities 1, 2 and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 and the severity strata are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI90 responder was defined as a participant achieving 90% or greater improvement from Baseline in EASI score.

    Time frame: Baseline to Weeks 2, 4 and 8

  14. VC Period: Percent Change From Baseline in EASI Score

    EASI scoring system examines 4 areas of the body (head/neck, trunk, upper limbs, and lower limbs) and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe). Half scores are allowed between severities 1, 2 and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 and the severity strata are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4 and 8

  15. VC Period: Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score

    The SCORAD is a tool to assess extent and severity of eczema. To determine the extent, the rule of nines or handprint method is used to assess eczema affected area (A). To determine disease severity (B) it evaluates 6 clinical characteristics: 1. redness, 2. swelling, 3. oozing/crusting, 4. scratch marks, 5. lichenification, and 6. dryness on a 4-point scale of 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), added to give B with maximum score of 18. Subjective symptoms (C) of itch and sleeplessness are assessed using a visual analogue scale where 0 is no itch (or no sleeplessness) and 10 is the worst imaginable itch (or sleeplessness), added to give C with maximum score of 20. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combined using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4 and 8

  16. VC Period: Change From Baseline in Itch NRS Score

    The Itch NRS is a daily participant-reported measure (24-hour recall), of the worst level of itch intensity using a diary. Participants are asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4 and 8

  17. VC Period: Time to Achieve Itch NRS Score Improvement of at Least 2, 3, or 4 Points

    The Itch NRS is a daily participant-reported measure (24-hour recall), of the worst level of itch intensity using a diary. Participants are asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours. Kaplan-Meier estimation method was used for analyses.

    Time frame: Up to Week 8

  18. VC Period: Change From Baseline in Skin Pain NRS Score

    The Skin Pain NRS is a daily patient-reported measure (24-hour recall), of the worst level of pain intensity from 0 (no pain) to 10 (worst imaginable pain) using a diary. Participants will be asked, "Rate the pain severity from your atopic dermatitis skin changes by selecting a number that best describes your worst level of pain in the past 24 hours." A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4 and 8

  19. VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep Disturbance (8b) 24-Hour Recall Score at Weeks 2 and 4

    The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance.

    Time frame: Weeks 2 and 4

  20. VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep-Related Impairment (8a) 24-Hour Recall Score at Weeks 2 and 4

    The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment.

    Time frame: Weeks 2 and 4

  21. VC Period: Change From Baseline in PROMIS Short Form - Sleep Disturbance (8b) 24-Hour Recall Score

    The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4 and 8

  22. VC Period: Change From Baseline in PROMIS Short Form - Sleep-Related Impairment (8a) 24-Hour Recall Score

    The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4 and 8

  23. LTS Period: Change From Baseline in PROMIS Short Form - Sleep-Related Impairment (8a) 7-Day Recall Score

    The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 12, 24, and 52

  24. LTS Period: Change From Baseline in PROMIS Short Form - Sleep Disturbance (8b) 7-Day Recall Score

    The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 12, 24, and 52

  25. VC Period: Change From Baseline in Atopic Dermatitis Afflicted Percentage of Body Surface Area (%BSA)

    Body surface area affected by AD was assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region was assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage was reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions. Use the percentage of skin affected for each region (0 to 100%) in EASI as follows: BSA Total = 0.1\*BSA head and neck + 0.3\*BSA trunk + 0.2\* BSA upper limbs + 0.4\*BSA lower limbs. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4 and 8

  26. LTS Period: Change From Baseline in Atopic Dermatitis Afflicted %BSA

    Body surface area affected by AD was assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region was assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage was reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions. Use the percentage of skin affected for each region (0 to 100%) in EASI as follows: BSA Total = 0.1\*BSA head and neck + 0.3\*BSA trunk + 0.2\* BSA upper limbs + 0.4\*BSA lower limbs. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  27. VC Period: Change From Baseline in Patient-Oriented Eczema Measure (POEM) Score

    The POEM is a 7-question quality-of-life assessment that asks how many days the participant has been bothered by various aspects of their skin condition during the past 7 days. It assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). High scores are indicative of more severe disease and poor quality of life. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4 and 8

  28. LTS Period: Change From Baseline in POEM Score

    The POEM is a 7-question quality-of-life assessment that asks how many days the participant has been bothered by various aspects of their skin condition during the past 7 days. It assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). High scores are indicative of more severe disease and poor quality of life. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 12, 24 and 52

  29. VC Period: Change From Baseline in Dermatology Life Quality Index (DLQI) Score

    The DLQI is a simple, 10 question (Q) validated quality-of-life questionnaire to measure how much the skin problem has affected the participant. It covers 6 domains including symptoms and feelings (Q1 and Q2), daily activities (Q3 and Q4), leisure (Q5 and Q6), work and school (Q7), personal relationships (Q8 and Q9), and treatment(Q10). The recall Period of this scale is over the last week. Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. Scores range from 0 ("no impact on participant's life") to 30 ("extremely large effect on participant's life"), and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.

    Time frame: Baseline, Weeks 2, 4, and 8

  30. LTS Period: Change From Baseline in DLQI Score

    The DLQI is a simple, 10 question (Q) validated quality-of-life questionnaire to measure how much the skin problem has affected the participant. It covers 6 domains including symptoms and feelings (Q1 and Q2), daily activities (Q3 and Q4), leisure (Q5 and Q6), work and school (Q7), personal relationships (Q8 and Q9), and treatment(Q10). The recall Period of this scale is over the last week. Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. Scores range from 0 ("no impact on participant's life") to 30 ("extremely large effect on participant's life"), and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.

    Time frame: Baseline, Weeks 12, 24, and 52

  31. VC Period: Change From Baseline in Children Dermatology Life Quality Index (CDLQI) Score

    CDLQI is the youth/children's version of the DLQI. The CDLQI is a simple 10 question (Q) validated quality-of-life questionnaire. It covers 6 domains including symptoms and feelings (Q1 and Q2), leisure (Q4, Q5, and Q6), school or holidays (Q7), personal relationships (Q3 and Q8), sleep (Q9) and treatment (Q10). Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. The total DLQI score is calculated by adding the score of each question resulting in a maximum score of 30 (extremely large effect on participant's life) and a minimum score of 0 (no impact on participant's life) and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.

    Time frame: Baseline, Weeks 2, 4, and 8

  32. LTS Period: Change From Baseline in CDLQI Score

    CDLQI is the youth/children's version of the DLQI. The CDLQI is a simple 10 question (Q) validated quality-of-life questionnaire. It covers 6 domains including symptoms and feelings (Q1 and Q2), leisure (Q4, Q5, and Q6), school or holidays (Q7), personal relationships (Q3 and Q8), sleep (Q9) and treatment (Q10). Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. The total DLQI score is calculated by adding the score of each question resulting in a maximum score of 30 (extremely large effect on participant's life) and a minimum score of 0 (no impact on participant's life) and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.

    Time frame: Baseline, Weeks 12, 24, and 52

  33. VC Period: Mean Patient Global Impression of Change (PGIC) Score at Weeks 2, 4, and 8

    The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. It is a 7-point scale where participants rate the questions as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The lower score indicates improvement.

    Time frame: Weeks 2, 4 and 8

  34. VC Period: Percentage of Participants With Each Score on the PGIC at Weeks 2, 4, and 8

    The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. It is a 7-point scale where participants rate the questions as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The lower score indicates improvement.

    Time frame: Weeks 2, 4 and 8

  35. VC Period: Percentage of Participants With a Score of Either 1 or 2 on the PGIC at Weeks 2, 4, and 8

    The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. It is a 7-point scale where participants rate the questions as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The lower score indicates improvement.

    Time frame: Weeks 2, 4 and 8

  36. VC Period: Change From Baseline in EuroQuality of Life Five Dimensions (EQ-5D-5L) Visual Analogue Scale (VAS) Score

    EQ-5D-5L questionnaire has 2 parts: EQ-5D-5L descriptive system \& EQ-VAS. EQ-5D is a validated, self-administered, generic utility questionnaire wherein participants rate their current health state based on 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. 5L indicates that for each dimension, there are 5 levels:1=no problems,2=slight problems,3=moderate problems,4=severe problems, and 5=extreme problems. EQ-5D-5L score is assessed using VAS that ranges from 0 to 100 millimetres (mm), where 0 indicates "worst health you can imagine" and 100 indicates "best health you can imagine". The participant was asked to indicate his/her health state over past 7 days in each of the 5 dimensions. Digits for the 5 dimensions can be combined into a 5-digit number that describes the participant's health state. In the EQ-VAS, participants had to record their health state on a scale ranging from 0 to 100. A positive change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4 and 8

  37. VC Period: Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) Version 2.0 (v2.0)

    The WPAI-SHP is a 6-item participant questionnaire developed to measure the effect of overall health and specific symptoms on productivity at work and regular activities outside of it in the past 7 days. The WPAI-SHP consists of 6 questions as follows: 1=currently employed; 2=hours missed due to AD; 3=hours missed other reasons; 4=hours actually worked; 5=degree AD affected productivity while working; 6=degree AD affected regular activities and the computed percentage, range for each sub scale is from 0 to 100, with higher values indicating greater impairment and less productivity. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4, and 8

  38. LTS Period: Change From Baseline in WPAI-SHP v2.0

    The WPAI-SHP is a 6-item participant questionnaire developed to measure the effect of overall health and specific symptoms on productivity at work and regular activities outside of it in the past 7 days. The WPAI-SHP consists of 6 questions as follows: 1=currently employed; 2=hours missed due to AD; 3=hours missed other reasons; 4=hours actually worked; 5=degree AD affected productivity while working; 6=degree AD affected regular activities and the computed percentage, range for each sub scale is from 0 to 100, with higher values indicating greater impairment and less productivity. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 12, 24, 36, and 52

  39. VC Period: Trough Plasma Concentrations of Ruxolitinib

    Plasma samples were collected just before the morning application of study drug during each specified time point.

    Time frame: Pre-dose at Weeks 2, 4 and 8

  40. LTS Period: Trough Plasma Concentrations of Ruxolitinib

    Plasma samples were collected just before the morning application of study drug during each specified time point.

    Time frame: Pre-dose at Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

07

Results

Posted Dec 17, 2021

Participant flow

A total of 618 participants were enrolled at 65 investigative sites in North America and Europe from December 20, 2018 to November 09, 2020.

Vehicle Control Period (Day 1 to Week 8)
Participant flow — Vehicle Control Period (Day 1 to Week 8)
MilestoneVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% Cream BIDLTS Period: Ruxolitinib 1.5% Cream BID
Started1242482460000
Completed1052092240000
Not completed1939220000
Withdrew: Adverse event1100000
Withdrew: Lost to follow-up31340000
Withdrew: Physician decision3010000
Withdrew: Protocol violation0200000
Withdrew: Withdrawal by subject1121150000
Withdrew: Reason not specified1220000
Long-Term Safety Period (Weeks 8 to 52)
Participant flow — Long-Term Safety Period (Weeks 8 to 52)
MilestoneVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% Cream BIDLTS Period: Ruxolitinib 1.5% Cream BID
Started0005352204221
Completed0003341151170
Not completed00020115351
Withdrew: Adverse event0000040
Withdrew: Lack of efficacy0001044
Withdrew: Lost to follow-up000421310
Withdrew: Physician decision0001042
Withdrew: Pregnancy0001001
Withdrew: Protocol violation0000010
Withdrew: Withdrawal by subject0001282634
Withdrew: Reason not specified0001110

Outcome measures

PrimaryVC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8

The IGA is an overall eczema severity rating on a 5-point scale ranging from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting. The IGA-TS is defined as an IGA score of 0 (clear skin) or 1 (almost clear skin) with ≥ 2 grade improvement from Baseline.

Time frame:
Baseline to Week 8
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 87.6 (3.5 to 14.0)39.0 (32.6 to 45.6)51.3 (44.6 to 58.0)
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Exact Logistic Regression · p = < 0.0001 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 8.84 · 95% CI 4.125 to 21.202
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Exact Logistic Regression · p = < 0.0001 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 15.80 · 95% CI 7.354 to 38.061
SecondaryVC Period: Percentage of Participants Who Achieved Eczema Area and Severity Index 75 (EASI75) at Week 8

EASI scoring system examines 4 areas of the body (head/neck, trunk, upper limbs, and lower limbs) and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe). Half scores are allowed between severities 1, 2 and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 and the severity strata are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI75 responder was defined as a participant achieving 75% or greater improvement from Baseline in EASI score.

Time frame:
Baseline to Week 8
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants Who Achieved Eczema Area and Severity Index 75 (EASI75) at Week 8
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
VC Period: Percentage of Participants Who Achieved Eczema Area and Severity Index 75 (EASI75) at Week 814.4 (8.6 to 22.1)51.5 (44.9 to 58.1)61.8 (55.2 to 68.2)
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Exact Logistic Regression · p = < 0.0001 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 6.84 · 95% CI 3.723 to 13.184
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Exact Logistic Regression · p = < 0.0001 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 10.67 · 95% CI 5.775 to 20.732
SecondaryVC Period: Percentage of Participants With a ≥ 4-Point Improvement in Itch Numerical Rating Scale (NRS) Score From Baseline to Week 8

The Itch NRS is a daily participant-reported measure (24-hour recall), of the worst level of itch intensity using a diary. Participants are asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours.

Time frame:
Baseline to Week 8
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants With a ≥ 4-Point Improvement in Itch Numerical Rating Scale (NRS) Score From Baseline to Week 8
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
VC Period: Percentage of Participants With a ≥ 4-Point Improvement in Itch Numerical Rating Scale (NRS) Score From Baseline to Week 816.342.750.7
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Exact Logistic Regression · p = < 0.0001 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 4.17 · 95% CI 2.045 to 9.036
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Exact Logistic Regression · p = < 0.0001 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 5.80 · 95% CI 2.833 to 12.657
SecondaryVC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form - Sleep Disturbance (8b - 24-Hour Recall) Score at Week 8

The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance.

Time frame:
Baseline to Week 8
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form - Sleep Disturbance (8b - 24-Hour Recall) Score at Week 8
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form - Sleep Disturbance (8b - 24-Hour Recall) Score at Week 819.120.725.6
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Exact Logistic Regression · p = 0.8553 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 1.11 · 95% CI 0.598 to 2.094
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Exact Logistic Regression · p = 0.2359 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 1.47 · 95% CI 0.805 to 2.741
SecondaryVC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep-Related Impairment (8a - 24-Hour Recall) Score at Week 8

The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment. Each item asks the participant to rate the severity of the participant's sleep impairment.

Time frame:
Baseline to Week 8
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep-Related Impairment (8a - 24-Hour Recall) Score at Week 8
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep-Related Impairment (8a - 24-Hour Recall) Score at Week 813.520.023.1
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Exact Logistic Regression · p = 0.1784 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 1.62 · 95% CI 0.827 to 3.342
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Exact Logistic Regression · p = 0.0472 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 1.96 · 95% CI 1.007 to 4.000
SecondaryVC Period: Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) and Treatment-Emergent Serious Adverse Event (SAE)

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or an important medical event may be considered serious when, based on appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above. A TEAE or treatment emergent SAE is any AE or SAE either reported for first time or worsening of a pre-existing event after first dose of study drug.

Time frame:
From date of randomization up to Week 8
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) and Treatment-Emergent Serious Adverse Event (SAE)
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
TEAE31.529.023.6
Treatment Emergent SAE0.01.20.4
SecondaryLTS Period: Percentage of Participants With at Least One TEAE and Treatment Emergent SAE

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or an important medical event may be considered serious when, based on appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above. A TEAE or treatment emergent SAE is any AE or SAE either reported for first time or worsening of a pre-existing event after first dose of study drug.

Time frame:
From first dose date in LTS Period (Week 8) until last follow-up visit (up to 52 weeks)
Reported as:
Number · percentage of participants
LTS Period: Percentage of Participants With at Least One TEAE and Treatment Emergent SAE
percentage of participantsLTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% Cream BIDLTS Period: Ruxolitinib 1.5% Cream BID
TEAE58.565.466.254.3
Treatment Emergent SAE3.80.02.51.4
SecondaryVC Period: Percentage of Participants Who Achieved an IGA-TS at Weeks 2 and 4

The IGA is an overall eczema severity rating on a 5-point scale ranging from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting. The IGA-TS is defined as an IGA score of 0 (clear skin) or 1 (almost clear skin) with ≥ 2 grade improvement from Baseline.

Time frame:
Baseline to Weeks 2 and 4
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants Who Achieved an IGA-TS at Weeks 2 and 4
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 24.217.325.0
Week 45.935.543.4
SecondaryVC Period: Percentage of Participants Achieving an IGA of 0 or 1

The IGA is an overall eczema severity rating on a 5-point scale ranging from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting.

Time frame:
Weeks 2, 4 and 8
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants Achieving an IGA of 0 or 1
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 29.324.234.6
Week 416.945.952.6
Week 816.151.162.3
SecondaryLTS Period: Percentage of Participants Achieving an IGA of 0 or 1

The IGA is an overall eczema severity rating on a 5-point scale ranging from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting.

Time frame:
Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Number · percentage of participants
LTS Period: Percentage of Participants Achieving an IGA of 0 or 1
percentage of participantsLTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% Cream BIDLTS Period: Ruxolitinib 1.5% Cream BID
Week 826.010.257.565.5
Week 1259.645.859.673.0
Week 1659.659.668.974.1
Week 2069.058.771.174.5
Week 2461.067.470.472.4
Week 2867.667.474.172.0
Week 3277.172.774.273.8
Week 3681.369.873.379.3
Week 4077.166.776.079.3
Week 4474.370.575.280.1
Week 4879.469.875.275.9
Week 5279.474.476.780.1
SecondaryVC Period: Percentage of Participants With a ≥ 4-Point Improvement in Itch NRS Score From Baseline to Weeks 2 and 4

The Itch NRS is a daily participant-reported measure (24-hour recall), of the worst level of itch intensity using a diary. Participants are asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours.

Time frame:
Baseline to Weeks 2 and 4
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants With a ≥ 4-Point Improvement in Itch NRS Score From Baseline to Weeks 2 and 4
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 25.027.432.2
Week 412.538.245.2
SecondaryVC Period: Percentage of Participants Who Achieved EASI50

EASI scoring system examines 4 areas of the body (head/neck, trunk, upper limbs, and lower limbs) and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe). Half scores are allowed between severities 1, 2 and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 and the severity strata are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI50 responder was defined as a participant achieving 50% or greater improvement from Baseline in EASI score.

Time frame:
Baseline to Weeks 2, 4 and 8
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants Who Achieved EASI50
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 216.145.553.5
Week 428.869.771.9
Week 833.975.879.8
SecondaryVC Period: Percentage of Participants Who Achieved EASI75 at Weeks 2 and 4

EASI scoring system examines 4 areas of the body (head/neck, trunk, upper limbs, and lower limbs) and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe). Half scores are allowed between severities 1, 2 and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 and the severity strata are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI75 responder was defined as a participant achieving 75% or greater improvement from Baseline in EASI score.

Time frame:
Baseline to Weeks 2 and 4
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants Who Achieved EASI75 at Weeks 2 and 4
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 24.225.531.6
Week 410.242.050.4
SecondaryVC Period: Percentage of Participants Who Achieved EASI90

EASI scoring system examines 4 areas of the body (head/neck, trunk, upper limbs, and lower limbs) and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe). Half scores are allowed between severities 1, 2 and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 and the severity strata are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI90 responder was defined as a participant achieving 90% or greater improvement from Baseline in EASI score.

Time frame:
Baseline to Weeks 2, 4 and 8
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants Who Achieved EASI90
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 20.810.815.8
Week 42.525.532.5
Week 84.235.143.4
SecondaryVC Period: Percent Change From Baseline in EASI Score

EASI scoring system examines 4 areas of the body (head/neck, trunk, upper limbs, and lower limbs) and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe). Half scores are allowed between severities 1, 2 and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 and the severity strata are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4 and 8
Reported as:
Least squares mean · percent change
VC Period: Percent Change From Baseline in EASI Score
percent changeVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Percent Change From Baseline at Week 2-13.95 ± 4.02-45.86 ± 2.84-49.08 ± 2.86
Percent Change From Baseline at Week 4-20.45 ± 3.62-65.00 ± 2.50-66.35 ± 2.51
Percent Change From Baseline at Week 8-28.84 ± 3.57-73.37 ± 2.50-74.84 ± 2.46
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = <0.0001 · Least squares mean difference: -31.91 · 95% CI -41.57 to -22.25The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = <0.0001 · Least squares mean difference: -35.13 · 95% CI -44.81 to -25.44The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = <0.0001 · Least squares mean difference: -44.56 · 95% CI -53.19 to -35.92The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = <0.0001 · Least squares mean difference: -45.91 · 95% CI -54.55 to -37.26The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = <0.0001 · Least squares mean difference: -44.53 · 95% CI -53.08 to -35.98The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = <0.0001 · Least squares mean difference: -46.00 · 95% CI -54.51 to -37.48The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
SecondaryVC Period: Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score

The SCORAD is a tool to assess extent and severity of eczema. To determine the extent, the rule of nines or handprint method is used to assess eczema affected area (A). To determine disease severity (B) it evaluates 6 clinical characteristics: 1. redness, 2. swelling, 3. oozing/crusting, 4. scratch marks, 5. lichenification, and 6. dryness on a 4-point scale of 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), added to give B with maximum score of 18. Subjective symptoms (C) of itch and sleeplessness are assessed using a visual analogue scale where 0 is no itch (or no sleeplessness) and 10 is the worst imaginable itch (or sleeplessness), added to give C with maximum score of 20. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combined using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4 and 8
Reported as:
Mean · percent change
VC Period: Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score
percent changeVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Percent Change From Baseline at Week 2-13.87 ± 24.816-39.62 ± 28.061-45.22 ± 28.461
Percent Change From Baseline at Week 4-21.79 ± 30.083-54.85 ± 29.803-58.76 ± 29.580
Percent Change From Baseline at Week 8-23.63 ± 33.918-63.71 ± 28.494-67.39 ± 29.098
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -39.4 · 95% CI -46.48 to -32.38P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -43.5 · 95% CI -50.51 to -36.53P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
SecondaryVC Period: Change From Baseline in Itch NRS Score

The Itch NRS is a daily participant-reported measure (24-hour recall), of the worst level of itch intensity using a diary. Participants are asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4 and 8
Reported as:
Least squares mean · score on a scale
VC Period: Change From Baseline in Itch NRS Score
score on a scaleVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 2-0.69 ± 0.21-2.21 ± 0.15-2.43 ± 0.15
Change From Baseline at Week 4-1.03 ± 0.23-2.82 ± 0.17-3.00 ± 0.17
Change From Baseline at Week 8-1.39 ± 0.25-3.28 ± 0.18-3.09 ± 0.17
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = <0.0001 · Least squares mean difference: -1.52 · 95% CI -2.02 to -1.01The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = <0.0001 · Least squares mean difference: -1.74 · 95% CI -2.24 to -1.24The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = <0.0001 · Least squares mean difference: -1.79 · 95% CI -2.36 to -1.23The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = <0.0001 · Least squares mean difference: -1.97 · 95% CI -2.53 to -1.40The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = <0.0001 · Least squares mean difference: -1.89 · 95% CI -2.49 to -1.29The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = <0.0001 · Least squares mean difference: -1.70 · 95% CI -2.30 to -1.10The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
SecondaryVC Period: Time to Achieve Itch NRS Score Improvement of at Least 2, 3, or 4 Points

The Itch NRS is a daily participant-reported measure (24-hour recall), of the worst level of itch intensity using a diary. Participants are asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours. Kaplan-Meier estimation method was used for analyses.

Time frame:
Up to Week 8
Reported as:
Median · days
VC Period: Time to Achieve Itch NRS Score Improvement of at Least 2, 3, or 4 Points
daysVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
≥ 2-Point Improvement in Itch NRS Score20.0 (13.0 to 24.0)5.0 (4.0 to 6.0)4.0 (4.0 to 5.0)
≥ 3-Point Improvement in Itch NRS Score44.0 (25.0 to NA)8.0 (6.0 to 13.0)8.0 (6.0 to 11.0)
≥ 4-Point Improvement in Itch NRS ScoreNA (NA to NA)16 (12 to 22)14 (10 to 18)
SecondaryVC Period: Change From Baseline in Skin Pain NRS Score

The Skin Pain NRS is a daily patient-reported measure (24-hour recall), of the worst level of pain intensity from 0 (no pain) to 10 (worst imaginable pain) using a diary. Participants will be asked, "Rate the pain severity from your atopic dermatitis skin changes by selecting a number that best describes your worst level of pain in the past 24 hours." A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4 and 8
Reported as:
Mean · score on a scale
VC Period: Change From Baseline in Skin Pain NRS Score
score on a scaleVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 2-0.53 ± 1.677-1.78 ± 2.145-1.73 ± 2.125
Change From Baseline at Week 4-0.93 ± 1.964-2.28 ± 2.449-2.27 ± 2.262
Change From Baseline at Week 8-1.35 ± 2.540-2.45 ± 2.575-2.37 ± 2.428
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -1.5 · 95% CI -1.94 to -0.97P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -1.2 · 95% CI -1.72 to -0.76P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
SecondaryVC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep Disturbance (8b) 24-Hour Recall Score at Weeks 2 and 4

The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance.

Time frame:
Weeks 2 and 4
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep Disturbance (8b) 24-Hour Recall Score at Weeks 2 and 4
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 210.014.618.0
Week 412.716.918.0
SecondaryVC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep-Related Impairment (8a) 24-Hour Recall Score at Weeks 2 and 4

The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment.

Time frame:
Weeks 2 and 4
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep-Related Impairment (8a) 24-Hour Recall Score at Weeks 2 and 4
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 27.210.713.2
Week 49.013.019.8
SecondaryVC Period: Change From Baseline in PROMIS Short Form - Sleep Disturbance (8b) 24-Hour Recall Score

The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4 and 8
Reported as:
Least squares mean · score on a scale
VC Period: Change From Baseline in PROMIS Short Form - Sleep Disturbance (8b) 24-Hour Recall Score
score on a scaleVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 2-1.32 ± 0.46-1.92 ± 0.33-2.30 ± 0.33
Change From Baseline at Week 4-2.02 ± 0.50-2.32 ± 0.35-2.88 ± 0.35
Change From Baseline at Week 8-2.60 ± 0.60-3.30 ± 0.42-3.40 ± 0.41
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = 0.2903 · Least squares mean difference: -0.60 · 95% CI -1.71 to 0.51The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = 0.0837 · Least squares mean difference: -0.98 · 95% CI -2.09 to 0.13The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = 0.6272 · Least squares mean difference: -0.30 · 95% CI -1.50 to 0.91The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = 0.1609 · Least squares mean difference: -0.86 · 95% CI -2.07 to 0.34The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = 0.3362 · Least squares mean difference: -0.70 · 95% CI -2.13 to 0.73The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = 0.2690 · Least squares mean difference: -0.80 · 95% CI -2.23 to 0.62The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
SecondaryVC Period: Change From Baseline in PROMIS Short Form - Sleep-Related Impairment (8a) 24-Hour Recall Score

The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4 and 8
Reported as:
Least squares mean · score on a scale
VC Period: Change From Baseline in PROMIS Short Form - Sleep-Related Impairment (8a) 24-Hour Recall Score
score on a scaleVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 2-0.80 ± 0.44-1.87 ± 0.31-2.00 ± 0.31
Change From Baseline at Week 4-1.37 ± 0.49-2.13 ± 0.35-2.91 ± 0.35
Change From Baseline at Week 8-2.08 ± 0.55-3.26 ± 0.39-3.31 ± 0.38
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = 0.0482 · Least squares mean difference: -1.07 · 95% CI -2.13 to -0.01The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = 0.0271 · Least squares mean difference: -1.20 · 95% CI -2.26 to -0.14The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = 0.2091 · Least squares mean difference: -0.76 · 95% CI -1.94 to 0.42The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = 0.0111 · Least squares mean difference: -1.53 · 95% CI -2.71 to -0.35The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Mixed-Model with Repeated Measures · p = 0.0802 · Least squares mean difference: -1.18 · 95% CI -2.51 to 0.14The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Mixed-Model with Repeated Measures · p = 0.0666 · Least squares mean difference: -1.24 · 95% CI -2.56 to 0.09The MMRM included the fixed effect of treatment, stratification factor, the visit, and treatment by visit interaction.
SecondaryLTS Period: Change From Baseline in PROMIS Short Form - Sleep-Related Impairment (8a) 7-Day Recall Score

The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 12, 24, and 52
Reported as:
Mean · score on a scale
LTS Period: Change From Baseline in PROMIS Short Form - Sleep-Related Impairment (8a) 7-Day Recall Score
score on a scaleLTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% Cream BIDLTS Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 12-1.73 ± 4.019-2.04 ± 6.282-0.32 ± 4.724-0.04 ± 3.914
Change From Baseline at Week 24-0.47 ± 4.695-1.04 ± 5.969-0.11 ± 5.1360.22 ± 4.868
Change From Baseline at Week 52-1.48 ± 5.304-2.33 ± 6.582-0.24 ± 5.660-0.69 ± 5.483
SecondaryLTS Period: Change From Baseline in PROMIS Short Form - Sleep Disturbance (8b) 7-Day Recall Score

The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 12, 24, and 52
Reported as:
Mean · score on a scale
LTS Period: Change From Baseline in PROMIS Short Form - Sleep Disturbance (8b) 7-Day Recall Score
score on a scaleLTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% Cream BIDLTS Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 12-2.00 ± 4.973-1.80 ± 5.588-0.37 ± 4.621-0.32 ± 4.466
Change From Baseline at Week 24-0.97 ± 6.188-1.87 ± 5.691-0.03 ± 4.6880.06 ± 5.376
Change From Baseline at Week 52-1.39 ± 7.198-2.88 ± 7.235-0.36 ± 6.049-0.42 ± 5.950
SecondaryVC Period: Change From Baseline in Atopic Dermatitis Afflicted Percentage of Body Surface Area (%BSA)

Body surface area affected by AD was assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region was assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage was reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions. Use the percentage of skin affected for each region (0 to 100%) in EASI as follows: BSA Total = 0.1\*BSA head and neck + 0.3\*BSA trunk + 0.2\* BSA upper limbs + 0.4\*BSA lower limbs. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4 and 8
Reported as:
Mean · % BSA
VC Period: Change From Baseline in Atopic Dermatitis Afflicted Percentage of Body Surface Area (%BSA)
% BSAVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 2-0.48 ± 3.008-2.92 ± 3.944-3.99 ± 4.636
Change From Baseline at Week 4-1.62 ± 3.338-4.77 ± 4.711-5.45 ± 5.223
Change From Baseline at Week 8-2.13 ± 4.671-6.00 ± 4.845-6.61 ± 5.479
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -3.9 · 95% CI -4.84 to -2.97P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -4.5 · 95% CI -5.47 to -3.63P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
SecondaryLTS Period: Change From Baseline in Atopic Dermatitis Afflicted %BSA

Body surface area affected by AD was assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region was assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage was reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions. Use the percentage of skin affected for each region (0 to 100%) in EASI as follows: BSA Total = 0.1\*BSA head and neck + 0.3\*BSA trunk + 0.2\* BSA upper limbs + 0.4\*BSA lower limbs. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Mean · % BSA
LTS Period: Change From Baseline in Atopic Dermatitis Afflicted %BSA
% BSALTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% Cream BIDLTS Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 12-3.89 ± 5.530-4.71 ± 4.980-6.61 ± 4.395-7.69 ± 5.106
Change From Baseline at Week 16-4.41 ± 5.553-5.47 ± 5.289-6.77 ± 5.270-7.80 ± 5.096
Change From Baseline at Week 20-4.88 ± 5.210-6.27 ± 6.193-7.48 ± 4.900-8.05 ± 4.920
Change From Baseline at Week 24-4.70 ± 4.775-6.37 ± 5.817-7.49 ± 4.988-8.00 ± 5.071
Change From Baseline at Week 28-4.59 ± 4.677-6.21 ± 6.597-7.48 ± 4.827-8.07 ± 5.099
Change From Baseline at Week 32-5.10 ± 5.203-6.79 ± 5.960-7.69 ± 4.891-7.89 ± 5.004
Change From Baseline at Week 36-4.65 ± 5.266-6.16 ± 6.045-7.79 ± 4.856-8.38 ± 5.119
Change From Baseline at Week 40-4.59 ± 5.196-6.42 ± 5.887-7.83 ± 4.976-8.44 ± 5.090
Change From Baseline at Week 44-5.18 ± 4.901-6.56 ± 6.200-7.92 ± 5.082-8.43 ± 5.122
Change From Baseline at Week 48-5.30 ± 5.130-6.61 ± 5.897-7.64 ± 5.380-8.33 ± 5.204
Change From Baseline at Week 52-5.12 ± 5.114-6.83 ± 5.837-7.92 ± 4.823-8.42 ± 4.973
SecondaryVC Period: Change From Baseline in Patient-Oriented Eczema Measure (POEM) Score

The POEM is a 7-question quality-of-life assessment that asks how many days the participant has been bothered by various aspects of their skin condition during the past 7 days. It assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). High scores are indicative of more severe disease and poor quality of life. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4 and 8
Reported as:
Mean · score on a scale
VC Period: Change From Baseline in Patient-Oriented Eczema Measure (POEM) Score
score on a scaleVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 2-2.06 ± 5.371-8.21 ± 6.694-8.86 ± 6.807
Change From Baseline at Week 4-4.01 ± 6.125-9.59 ± 6.883-9.97 ± 6.839
Change From Baseline at Week 8-4.18 ± 6.574-10.34 ± 6.835-10.08 ± 7.167
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -6.1 · 95% CI -7.38 to -4.86P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -5.9 · 95% CI -7.17 to -4.67P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
SecondaryLTS Period: Change From Baseline in POEM Score

The POEM is a 7-question quality-of-life assessment that asks how many days the participant has been bothered by various aspects of their skin condition during the past 7 days. It assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). High scores are indicative of more severe disease and poor quality of life. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 12, 24 and 52
Reported as:
Mean · score on a scale
LTS Period: Change From Baseline in POEM Score
score on a scaleLTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% Cream BIDLTS Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 12-5.65 ± 7.460-6.04 ± 7.269-9.72 ± 6.571-10.58 ± 6.883
Change From Baseline at Week 24-4.03 ± 7.006-5.71 ± 6.567-10.30 ± 6.675-10.58 ± 6.848
Change From Baseline at Week 52-6.15 ± 7.304-6.28 ± 7.340-10.29 ± 6.187-10.65 ± 6.699
SecondaryVC Period: Change From Baseline in Dermatology Life Quality Index (DLQI) Score

The DLQI is a simple, 10 question (Q) validated quality-of-life questionnaire to measure how much the skin problem has affected the participant. It covers 6 domains including symptoms and feelings (Q1 and Q2), daily activities (Q3 and Q4), leisure (Q5 and Q6), work and school (Q7), personal relationships (Q8 and Q9), and treatment(Q10). The recall Period of this scale is over the last week. Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. Scores range from 0 ("no impact on participant's life") to 30 ("extremely large effect on participant's life"), and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.

Time frame:
Baseline, Weeks 2, 4, and 8
Reported as:
Mean · score on a scale
VC Period: Change From Baseline in Dermatology Life Quality Index (DLQI) Score
score on a scaleVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 2-0.91 ± 4.679-5.40 ± 5.874-5.14 ± 5.394
Change From Baseline at Week 4-3.00 ± 4.962-6.62 ± 5.966-6.16 ± 5.771
Change From Baseline at Week 8-3.30 ± 5.353-7.18 ± 6.004-6.41 ± 5.731
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -3.3 · 95% CI -4.19 to -2.32P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -2.8 · 95% CI -3.67 to -1.83P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
SecondaryLTS Period: Change From Baseline in DLQI Score

The DLQI is a simple, 10 question (Q) validated quality-of-life questionnaire to measure how much the skin problem has affected the participant. It covers 6 domains including symptoms and feelings (Q1 and Q2), daily activities (Q3 and Q4), leisure (Q5 and Q6), work and school (Q7), personal relationships (Q8 and Q9), and treatment(Q10). The recall Period of this scale is over the last week. Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. Scores range from 0 ("no impact on participant's life") to 30 ("extremely large effect on participant's life"), and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.

Time frame:
Baseline, Weeks 12, 24, and 52
Reported as:
Mean · score on a scale
LTS Period: Change From Baseline in DLQI Score
score on a scaleLTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% Cream BIDLTS Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 12-2.09 ± 3.611-2.79 ± 5.542-7.07 ± 5.931-7.06 ± 6.044
Change From Baseline at Week 24-1.22 ± 3.293-3.08 ± 3.759-7.17 ± 6.152-7.01 ± 5.754
Change From Baseline at Week 52-3.09 ± 3.753-3.20 ± 4.234-7.49 ± 5.776-7.28 ± 6.196
SecondaryVC Period: Change From Baseline in Children Dermatology Life Quality Index (CDLQI) Score

CDLQI is the youth/children's version of the DLQI. The CDLQI is a simple 10 question (Q) validated quality-of-life questionnaire. It covers 6 domains including symptoms and feelings (Q1 and Q2), leisure (Q4, Q5, and Q6), school or holidays (Q7), personal relationships (Q3 and Q8), sleep (Q9) and treatment (Q10). Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. The total DLQI score is calculated by adding the score of each question resulting in a maximum score of 30 (extremely large effect on participant's life) and a minimum score of 0 (no impact on participant's life) and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.

Time frame:
Baseline, Weeks 2, 4, and 8
Reported as:
Mean · score on a scale
VC Period: Change From Baseline in Children Dermatology Life Quality Index (CDLQI) Score
score on a scaleVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 2-1.67 ± 5.416-3.45 ± 4.570-3.58 ± 4.032
Change From Baseline at Week 4-3.10 ± 6.488-4.82 ± 4.934-4.52 ± 5.221
Change From Baseline at Week 8-2.36 ± 7.500-4.56 ± 5.061-4.12 ± 6.418
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · ANCOVA · p = 0.0099 · Least squares mean difference: -4.1 · 95% CI -7.24 to -1.03P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · ANCOVA · p = 0.0542 · Least squares mean difference: -3.1 · 95% CI -6.30 to 0.06P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
SecondaryLTS Period: Change From Baseline in CDLQI Score

CDLQI is the youth/children's version of the DLQI. The CDLQI is a simple 10 question (Q) validated quality-of-life questionnaire. It covers 6 domains including symptoms and feelings (Q1 and Q2), leisure (Q4, Q5, and Q6), school or holidays (Q7), personal relationships (Q3 and Q8), sleep (Q9) and treatment (Q10). Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. The total DLQI score is calculated by adding the score of each question resulting in a maximum score of 30 (extremely large effect on participant's life) and a minimum score of 0 (no impact on participant's life) and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life.

Time frame:
Baseline, Weeks 12, 24, and 52
Reported as:
Mean · score on a scale
LTS Period: Change From Baseline in CDLQI Score
score on a scaleLTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% Cream BIDLTS Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 12-7.50 ± 2.121-4.88 ± 5.436-5.54 ± 5.153-5.57 ± 5.482
Change From Baseline at Week 24-8.50 ± 2.121-4.88 ± 4.549-5.72 ± 6.066-5.68 ± 7.326
Change From Baseline at Week 52-8.00 ± 1.414-6.38 ± 9.023-5.35 ± 4.902-6.57 ± 5.983
SecondaryVC Period: Mean Patient Global Impression of Change (PGIC) Score at Weeks 2, 4, and 8

The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. It is a 7-point scale where participants rate the questions as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The lower score indicates improvement.

Time frame:
Weeks 2, 4 and 8
Reported as:
Mean · score on a scale
VC Period: Mean Patient Global Impression of Change (PGIC) Score at Weeks 2, 4, and 8
score on a scaleVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 23.32 ± 1.2682.19 ± 1.0191.95 ± 0.980
Week 42.99 ± 1.2591.95 ± 0.9801.71 ± 0.852
Week 82.93 ± 1.3801.73 ± 0.9061.70 ± 0.909
SecondaryVC Period: Percentage of Participants With Each Score on the PGIC at Weeks 2, 4, and 8

The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. It is a 7-point scale where participants rate the questions as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The lower score indicates improvement.

Time frame:
Weeks 2, 4 and 8
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants With Each Score on the PGIC at Weeks 2, 4, and 8
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 2 - Very Much Improved: 14.632.141.0
Week 2 - Much Improved: 220.227.130.9
Week 2 - Minimally Improved: 338.532.120.7
Week 2 - No Change: 421.17.86.5
Week 2 - Minimally Worse: 57.30.50.9
Week 2 - Much Worse: 67.30.50.0
Week 2 - Very Much Worse: 70.90.00.0
Week 4 - Very Much Improved: 110.041.949.1
Week 4 - Much Improved: 229.028.635.2
Week 4 - Minimally Improved: 329.022.112.0
Week 4 - No Change: 420.06.92.8
Week 4 - Minimally Worse: 58.00.50.9
Week 4 - Much Worse: 64.00.00.0
Week 4 - Very Much Worse: 70.00.00.0
Week 8 - Very Much Improved: 116.852.751.6
Week 8 - Much Improved: 224.826.132.6
Week 8 - Minimally Improved: 323.816.312.1
Week 8 - No Change: 422.84.91.9
Week 8 - Minimally Worse: 57.90.01.4
Week 8 - Much Worse: 63.00.00.5
Week 8 - Very Much Worse: 71.00.00.0
SecondaryVC Period: Percentage of Participants With a Score of Either 1 or 2 on the PGIC at Weeks 2, 4, and 8

The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. It is a 7-point scale where participants rate the questions as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The lower score indicates improvement.

Time frame:
Weeks 2, 4 and 8
Reported as:
Number · percentage of participants
VC Period: Percentage of Participants With a Score of Either 1 or 2 on the PGIC at Weeks 2, 4, and 8
percentage of participantsVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 224.8 (17.0 to 34.0)59.2 (52.3 to 65.8)71.9 (65.4 to 77.8)
Week 439.0 (29.4 to 49.3)70.5 (64.0 to 76.5)84.3 (78.7 to 88.8)
Week 841.6 (31.9 to 51.8)78.8 (72.5 to 84.2)84.2 (78.6 to 88.8)
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · Exact Logistic Regression · p = <0.0001 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 5.16 · 95% CI 2.987 to 9.049
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · Exact Logistic Regression · p = <0.0001 (The unadjusted p-values between each treatment group and vehicle were calculated based on Exact Logistic Regression including treatment and stratification factors to test the treatment difference.) · Odds ratio (or): 7.47 · 95% CI 4.230 to 13.415
SecondaryVC Period: Change From Baseline in EuroQuality of Life Five Dimensions (EQ-5D-5L) Visual Analogue Scale (VAS) Score

EQ-5D-5L questionnaire has 2 parts: EQ-5D-5L descriptive system \& EQ-VAS. EQ-5D is a validated, self-administered, generic utility questionnaire wherein participants rate their current health state based on 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. 5L indicates that for each dimension, there are 5 levels:1=no problems,2=slight problems,3=moderate problems,4=severe problems, and 5=extreme problems. EQ-5D-5L score is assessed using VAS that ranges from 0 to 100 millimetres (mm), where 0 indicates "worst health you can imagine" and 100 indicates "best health you can imagine". The participant was asked to indicate his/her health state over past 7 days in each of the 5 dimensions. Digits for the 5 dimensions can be combined into a 5-digit number that describes the participant's health state. In the EQ-VAS, participants had to record their health state on a scale ranging from 0 to 100. A positive change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4 and 8
Reported as:
Mean · score on a scale
VC Period: Change From Baseline in EuroQuality of Life Five Dimensions (EQ-5D-5L) Visual Analogue Scale (VAS) Score
score on a scaleVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Change From Baseline at Week 21.43 ± 13.9756.16 ± 14.4096.98 ± 15.956
Change From Baseline at Week 43.31 ± 15.0616.38 ± 17.5128.55 ± 17.244
Change From Baseline at Week 82.97 ± 15.9467.16 ± 18.2458.36 ± 16.767
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · ANCOVA · p = 0.0150 · Least squares mean difference: 4.4 · 95% CI 0.85 to 7.86P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · ANCOVA · p = 0.0044 · Least squares mean difference: 5.1 · 95% CI 1.59 to 8.54P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
SecondaryVC Period: Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) Version 2.0 (v2.0)

The WPAI-SHP is a 6-item participant questionnaire developed to measure the effect of overall health and specific symptoms on productivity at work and regular activities outside of it in the past 7 days. The WPAI-SHP consists of 6 questions as follows: 1=currently employed; 2=hours missed due to AD; 3=hours missed other reasons; 4=hours actually worked; 5=degree AD affected productivity while working; 6=degree AD affected regular activities and the computed percentage, range for each sub scale is from 0 to 100, with higher values indicating greater impairment and less productivity. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4, and 8
Reported as:
Mean · score on a scale
VC Period: Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) Version 2.0 (v2.0)
score on a scaleVC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Percent Work Time Missed Due to AD: Change From Baseline at Week 24.77 ± 23.3480.64 ± 19.1902.53 ± 17.803
Percent Work Time Missed Due to AD: Change From Baseline at Week 43.22 ± 22.497-0.15 ± 22.2994.31 ± 19.679
Percent Work Time Missed Due to AD: Change From Baseline at Week 810.03 ± 24.4773.50 ± 24.7603.51 ± 18.479
Percent Impairment While Working Due to AD: Change From Baseline at Week 2-4.49 ± 25.500-12.76 ± 21.371-13.24 ± 19.958
Percent Impairment While Working Due to AD: Change From Baseline at Week 4-12.05 ± 24.514-15.25 ± 22.648-18.10 ± 19.832
Percent Impairment While Working Due to AD: Change From Baseline at Week 8-10.93 ± 25.618-18.83 ± 23.365-17.32 ± 19.013
Percent Overall Work Impairment Due to AD: Change From Baseline at Week 2-2.78 ± 31.057-12.58 ± 24.670-11.10 ± 23.717
Percent Overall Work Impairment Due to AD: Change From Baseline at Week 4-10.41 ± 26.627-15.14 ± 25.543-16.19 ± 22.037
Percent Overall Work Impairment Due to AD: Change From Baseline at Week 8-2.06 ± 29.625-17.00 ± 25.916-13.65 ± 22.476
Percent Activity Impairment Due to AD: Change From Baseline at Week 2-4.63 ± 21.243-12.79 ± 23.462-16.68 ± 23.295
Percent Activity Impairment Due to AD: Change From Baseline at Week 4-8.38 ± 20.981-17.24 ± 24.715-18.70 ± 23.550
Percent Activity Impairment Due to AD: Change From Baseline at Week 8-9.50 ± 25.361-19.66 ± 25.157-18.60 ± 25.557
Statistical analysis
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · ANCOVA · p = 0.1420 · Least squares mean difference: -5.6 · 95% CI -13.12 to 1.89P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · ANCOVA · p = 0.0375 · Least squares mean difference: -8.0 · 95% CI -15.51 to -0.47P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · ANCOVA · p = 0.0012 · Least squares mean difference: -9.1 · 95% CI -14.48 to -3.63P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · ANCOVA · p = 0.0095 · Least squares mean difference: -7.2 · 95% CI -12.58 to -1.77P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -15.2 · 95% CI -22.69 to -7.73P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · ANCOVA · p = 0.0010 · Least squares mean difference: -12.6 · 95% CI -20.10 to -5.18P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 0.75% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -12.1 · 95% CI -16.18 to -7.95P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
  • VC Period: Vehicle Cream BID vs VC Period: Ruxolitinib 1.5% Cream BID · ANCOVA · p = <0.0001 · Least squares mean difference: -10.4 · 95% CI -14.53 to -6.37P-value was analyzed using ANCOVA model with treatment, stratification factors and Baseline score as covariates if applicable.
SecondaryLTS Period: Change From Baseline in WPAI-SHP v2.0

The WPAI-SHP is a 6-item participant questionnaire developed to measure the effect of overall health and specific symptoms on productivity at work and regular activities outside of it in the past 7 days. The WPAI-SHP consists of 6 questions as follows: 1=currently employed; 2=hours missed due to AD; 3=hours missed other reasons; 4=hours actually worked; 5=degree AD affected productivity while working; 6=degree AD affected regular activities and the computed percentage, range for each sub scale is from 0 to 100, with higher values indicating greater impairment and less productivity. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 12, 24, 36, and 52
Reported as:
Mean · score on a scale
LTS Period: Change From Baseline in WPAI-SHP v2.0
score on a scaleLTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% Cream BIDLTS Period: Ruxolitinib 1.5% Cream BID
Percent Work Time Missed Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 12-4.26 ± 24.958-0.81 ± 17.257-0.17 ± 24.5813.48 ± 16.470
Percent Work Time Missed Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 24-2.06 ± 28.778-11.35 ± 22.947-0.38 ± 23.5115.13 ± 24.419
Percent Work Time Missed Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 36-1.04 ± 23.312-5.44 ± 27.625-0.02 ± 20.4103.37 ± 20.967
Percent Work Time Missed Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 52-2.29 ± 25.1483.60 ± 24.1860.50 ± 28.3486.36 ± 21.806
Percent Impairment While Working Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 12-5.91 ± 10.075-13.50 ± 29.784-19.87 ± 21.572-22.02 ± 19.652
Percent Impairment While Working Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 24-7.14 ± 22.835-16.47 ± 18.007-19.74 ± 23.719-22.56 ± 22.433
Percent Impairment While Working Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 36-7.33 ± 15.337-11.43 ± 21.432-18.79 ± 21.232-24.61 ± 20.359
Percent Impairment While Working Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 52-16.00 ± 24.129-13.85 ± 17.578-20.00 ± 25.312-21.86 ± 25.836
Percent Overall Work Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 12-11.64 ± 20.194-10.72 ± 23.285-17.40 ± 23.123-17.91 ± 24.692
Percent Overall Work Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 24-10.99 ± 33.070-25.22 ± 25.009-17.83 ± 27.226-19.31 ± 26.893
Percent Overall Work Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 36-7.77 ± 25.443-15.27 ± 30.360-17.70 ± 23.161-21.84 ± 27.812
Percent Overall Work Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 52-17.29 ± 33.754-10.17 ± 27.793-18.62 ± 28.397-16.20 ± 32.591
Percent Activity Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 12-7.78 ± 24.016-11.74 ± 22.736-21.17 ± 25.287-21.92 ± 26.378
Percent Activity Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 24-7.18 ± 26.552-13.78 ± 19.690-22.42 ± 25.547-22.32 ± 26.481
Percent Activity Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 36-10.65 ± 23.655-15.24 ± 20.150-23.43 ± 25.748-25.34 ± 26.927
Percent Activity Impairment Due to AD: Change From Baseline in WPAI-SHP v2.0 at Week 52-10.88 ± 28.001-14.88 ± 20.044-22.95 ± 24.656-23.93 ± 27.743
SecondaryVC Period: Trough Plasma Concentrations of Ruxolitinib

Plasma samples were collected just before the morning application of study drug during each specified time point.

Time frame:
Pre-dose at Weeks 2, 4 and 8
Reported as:
Mean · nanomole per litre (nM)
VC Period: Trough Plasma Concentrations of Ruxolitinib
nanomole per litre (nM)VC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BID
Week 225.2 ± 37.438.5 ± 64.5
Week 422.6 ± 35.241.8 ± 83.6
Week 822.4 ± 36.136.1 ± 66.6
SecondaryLTS Period: Trough Plasma Concentrations of Ruxolitinib

Plasma samples were collected just before the morning application of study drug during each specified time point.

Time frame:
Pre-dose at Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Mean · nM
LTS Period: Trough Plasma Concentrations of Ruxolitinib
nMLTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BIDLTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BIDLTS Period: Ruxolitinib 0.75% Cream BIDLTS Period: Ruxolitinib 1.5% Cream BID
Week 1213.8 ± 22.723.9 ± 55.214.3 ± 26.922.6 ± 46.6
Week 1612.3 ± 22.816.1 ± 27.715.1 ± 28.323.9 ± 45.9
Week 2018.8 ± 41.025.3 ± 43.913.6 ± 20.526.8 ± 55.9
Week 2411.7 ± 26.027.6 ± 62.418.5 ± 49.825.7 ± 56.9
Week 2820.4 ± 39.917.6 ± 32.216.1 ± 36.120.8 ± 39.8
Week 3214.6 ± 30.626.4 ± 51.314.0 ± 23.225.9 ± 67.8
Week 3611.4 ± 23.729.9 ± 52.815.0 ± 28.422.0 ± 40.1
Week 4012.6 ± 36.732.8 ± 59.420.0 ± 51.126.3 ± 59.4
Week 4415.9 ± 31.923.0 ± 33.714.8 ± 28.824.1 ± 40.9
Week 4816.8 ± 38.635.7 ± 64.523.4 ± 58.126.3 ± 54.3
Week 5212.9 ± 21.835.7 ± 65.217.7 ± 33.923.3 ± 48.1

Adverse events

Collected over Up to 60 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vehicle Cream BID0/124 (0%)0/124 (0%)9/124 (7.3%)
Ruxolitinib 0.75% Cream BID0/301 (0%)8/301 (2.7%)49/301 (16.3%)
Ruxolitinib 1.5% Cream BID0/298 (0%)4/298 (1.3%)51/298 (17.1%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventVehicle Cream BIDRuxolitinib 0.75% Cream BIDRuxolitinib 1.5% Cream BID
ArrhythmiaCardiac disorders0/1240/3011/298
Cerebrovascular accidentNervous system disorders0/1241/3011/298
Chronic tonsillitisInfections and infestations0/1240/3011/298
Deep vein thrombosisVascular disorders0/1240/3011/298
DyspnoeaRespiratory, thoracic and mediastinal disorders0/1240/3011/298
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/1240/3011/298
Ankle fractureInjury, poisoning and procedural complications0/1241/3010/298
Meniscus injuryInjury, poisoning and procedural complications0/1241/3010/298
Myocardial infarctionCardiac disorders0/1241/3010/298
PneumoniaInfections and infestations0/1241/3010/298
Most frequent other events
Most frequent other events
EventVehicle Cream BIDRuxolitinib 0.75% Cream BIDRuxolitinib 1.5% Cream BID
NasopharyngitisInfections and infestations0/12428/30127/298
Upper respiratory tract infectionInfections and infestations1/12423/30123/298
Application site painGeneral disorders8/1242/3012/298

Baseline characteristics

Intent-to-treat (ITT) population included all participants who were randomized to the study.

Age, Continuous
Age, Continuous(years)VC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BIDTotal
Mean38.9 ± 18.9035.8 ± 18.4535.9 ± 18.0136.4 ± 18.38
Sex: Female, Male
Sex: Female, Male(Participants)VC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BIDTotal
Female80150150380
Male449896238
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)VC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BIDTotal
Ethnicity — Hispanic or Latino17313078
Ethnicity — Not Hispanic or Latino107217216540
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)VC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BIDTotal
Race — White/Caucasian85174178437
Race — Black/African-American326357152
Race — Asian26614
Race — American-Indian/Alaska Native0011
Race — Native Hawaiian/Pacific Islander2002
Race — Other35412
Body Mass Index
Body Mass Index(Kilograms per square metre (kg/m^2))VC Period: Vehicle Cream BIDVC Period: Ruxolitinib 0.75% Cream BIDVC Period: Ruxolitinib 1.5% Cream BIDTotal
Mean27.75 ± 6.73727.60 ± 7.09128.01 ± 7.49527.80 ± 7.177
08

Study locations

66 sites
  • University Of Alabama At Birmingham
    Birmingham, Alabama 35233, United States
  • Center For Dermatology Cosmetic And Laser Surgery
    Fremont, California 94538, United States
  • Marvel Clinical Research - Clinedge - PPDS
    Huntington Beach, California 92647, United States
  • Allergy And Asthma Associates Of Southern California - CRN
    Mission Viejo, California 92691, United States
  • Synexus Clinical Research US Inc. Santa Rosa
    Santa Rosa, California 95405, United States
  • Olympian Clinical Research
    Largo, Florida 33770, United States
  • San Marcus Research Clinic Inc
    Miami Lakes, Florida 33014, United States
  • Well Pharma Medical Research Corporation
    South Miami, Florida 33143, United States
  • Forward Clinical Trials Inc
    Tampa, Florida 33624, United States
  • Clinical Research Atlanta - ERN - PPDS
    Stockbridge, Georgia 30281, United States
  • Northwest Clinical Trials Clinedge
    Boise, Idaho 83704, United States
  • Randall Dermatology
    West Lafayette, Indiana 47906, United States
  • Derm Research LLC
    Louisville, Kentucky 40217, United States
  • Dermatology Specialists PSC
    Louisville, Kentucky 40241, United States
  • Michael W Simon MD Office
    Nicholasville, Kentucky 40356, United States
  • Delricht Clinical Research - Clinedge - PPDS Baton Rouge
    Baton Rouge, Louisiana 70809, United States
  • Hamzavi Dermatology
    Fort Gratiot, Michigan 48059, United States
  • Jubilee Clinical Research - BTC - PPDS
    Las Vegas, Nevada 89106, United States
  • ActivMed Practices & Research Inc
    Portsmouth, New Hampshire 03801, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • Skin Laser and Surgery specialists of New York and New Jersey LLC
    Hackensack, New Jersey 07601, United States
  • Derm Research Center Of New York Inc
    Stony Brook, New York 11790, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27516, United States
  • Synexus Clinical Research US, Inc. - Cincinnati
    Cincinnati, Ohio 45236, United States
  • Ohio Pediatric Research Association
    Dayton, Ohio 45414, United States
  • Synexus Clinical Research US, Inc. - Anderson
    Anderson, South Carolina 29621, United States
  • International Clinical Research Tennessee LLC
    Murfreesboro, Tennessee 37130, United States
  • Epiphany Dermatology Fort Worth
    Fort Worth, Texas 76244, United States
  • Dermatology Clinical Research Center of San Antonio
    San Antonio, Texas 78229, United States
  • Center for Clinical Studies
    Webster, Texas 77598, United States
  • Tanner Clinic
    Layton, Utah 84041, United States
  • Advanced Research Institute
    Ogden, Utah 84405, United States
  • PI Coor Clinical Research LLC
    Burke, Virginia 22015, United States
  • Clinical Research Partners LLC
    Richmond, Virginia 23220, United States
  • Dermatology Specialists of Spokane
    Spokane, Washington 99202, United States
  • Medical Center Unimed EOOD
    Sevlievo, Gabrovo 5400, Bulgaria
  • Medical Center Excelsior OOD - PPDS
    Sofia, 1421, Bulgaria
  • Diagnostic Consultative Center XXVIII - Sofia - EOOD
    Sofia, 1592, Bulgaria
  • Synexus - Medical Center Synexus Sofia EOOD
    Sofia, 1784, Bulgaria
  • Synexus - Medical Centre Synexus Sofia EOOD (branch - Stara Zagora)
    Stara Zagora, 6000, Bulgaria
  • Wiseman Dermatology Research Inc.
    Winnipeg, Manitoba R3M 3Z4, Canada
  • The Centre For Clinical Trials Inc.
    Oakville, L617W5, Canada
  • Dermatology Ottawa Research Centre
    Ottawa, K2C 3N2, Canada
  • Dermamedica, s.r.o. - Kozni Ambulance Nachod
    Nachod, 547 01, Czechia
  • CTCenter MaVe s.r.o.
    Olomouc, 779 00, Czechia
  • CCR Ostrava, s.r.o.
    Ostrava, 702 00, Czechia
  • Synexus Czech s.r.o.
    Prague 2, 120 00, Czechia
  • Synexus Affiliate - CLINTRIAL s.r.o.
    Praha, 100 00, Czechia
  • Charité - Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • Hautarztpraxis Mahlow
    Brandenburg, 15831, Germany
  • Universitatsklinikum Schleswig-Holstein
    Kiel, 24105, Germany
  • Centrum Medyczne Matusiak
    Wroclaw, Dolnoslaskie 50-566, Poland
  • Synexus Affiliate - Bialystok - ClinicMed Daniluk, Nowak Spółka Jawna
    Bialystok, 15-879, Poland
  • Centrum Badan Klinicznych PI-House sp. z o.o.
    Gdansk, 80-546, Poland
  • Synexus - Gdynia
    Gdynia, 81-537, Poland
  • Centrum Medyczne Angelius Provita
    Katowice, 40-611, Poland
  • Synexus Affiliate - Krakowskie Centrum Medyczne
    Krakow, 31-501, Poland
  • Twoja Przychodnia - Szczecińskie Centrum Medyczne
    Szczecin, 71-434, Poland
  • Synexus - Warsaw
    Warszawa, 01-192, Poland
  • EMC Instytut Medyczny S.A.
    Wroclaw, 50-220, Poland
  • Wro Medica
    Wroclaw, 51-685, Poland
  • Hospital de Manises
    Manises, Valencia 46940, Spain
  • Hospital General Universitario de Alicante
    Alicante, 3010, Spain
  • Hospital de La Santa Creu i Sant Pau
    Barcelona, 08025, Spain
  • Hospital General Universitario Reina Sofia
    Cordoba, 14001, Spain
  • Hospital Universitario La Paz - PPDS
    Madrid, 28046, Spain
09

References and documents

Publications

  • Bloudek L, Eichenfield LF, Silverberg JI, Joish VN, Lofland JH, Sun K, Augustin M, Migliaccio-Walle K, Sullivan SD. Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies. Am J Clin Dermatol. 2023 Jan;24(1):109-117. doi: 10.1007/s40257-022-00734-8. Epub 2022 Oct 20. PubMed 36264430 ↗
  • Gong X, Chen X, Kuligowski ME, Liu X, Liu X, Cimino E, McGee R, Yeleswaram S. Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies. Am J Clin Dermatol. 2021 Jul;22(4):555-566. doi: 10.1007/s40257-021-00610-x. Epub 2021 May 12. PubMed 33982267 ↗
  • Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM, Forman SB, Venturanza ME, Sun K, Kuligowski ME, Simpson EL. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021 Oct;85(4):863-872. doi: 10.1016/j.jaad.2021.04.085. Epub 2021 May 4. PubMed 33957195 ↗
  • Scuron MD, Fay BL, Connell AJ, Peel MT, Smith PA. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis. Front Immunol. 2021 Feb 15;11:620098. doi: 10.3389/fimmu.2020.620098. eCollection 2020. PubMed 33658996 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Nov 2019, 10 months.

Results were first posted in Dec 2021, 2 years after primary completion. A results delay was requested in Nov 2020.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 10 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2018
First posted
Nov 19, 2018
StartActual
Dec 20, 2018
Primary completionActual
Nov 18, 2019
CompletionActual
Nov 9, 2020
Results delay requested
Nov 17, 2020
Results first posted
Dec 17, 2021
Last update
Sep 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03745651
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Nov 19, 2018
Start date
Dec 20, 2018
Primary completion
Nov 18, 2019
Completion
Nov 9, 2020
Results posted
Dec 17, 2021
Last update
Sep 28, 2023

Study contacts

Michael E. Kuligowski, MD, PhD, MBA
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion